Pure Global
NCT06421701

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

A Clinical Study of Anti-CD19 CAR-NK Cells in the Treatment of Refractory/Relapsed Systemic Lupus Erythematosus
Second Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
anti-CD19 CAR-NK cells
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Location
Hangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
May 31, 2026
Enrollment
10 participants
Primary outcome

The proportion of subjects with DLT,The proportion of subjects with adverse events

Summary

This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this
 study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with
 refractory/relapsed systemic lupus erythematosus.

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06421701
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06421701 through Pure Global AI's free database. This Phase 1 trial is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.